JAK-STAT1 as Therapeutic Target for EGFR Deficiency-Associated Inflammation and Scarring Alopecia

    November 2024 in “ EMBO Molecular Medicine
    Karoline Strobl, Jörg Klufa, Regina Jin, Lena Artner-Gent, Dana Krauß, Philipp Novoszel, Johanna Strobl, Georg Stary, Igor Vujic, Johannes Griss, Martin Holcmann, Matthias Farlik, Bernhard Homey, Maria Sibilia, Thomas Bauer
    Studysummary In this study, researchers found that disrupting EGFR signaling in mice led to increased inflammation and hair follicle damage but that inhibiting the JAK-STAT1 pathway could restore hair growth and skin function. Our plain-language summary of this paper — not a Tressless recommendation.
    The study explores the JAK-STAT1 pathway's role in scarring alopecia linked to EGFR deficiency, revealing that EGFR signaling disruption leads to JAK-STAT1 hypersensitivity and inflammation from CD8 T-cells and NK-cells, damaging hair follicle stem cells. In mouse models, genetic depletion or therapeutic inhibition of JAK1/2 reduces inflammation, restores skin function, and promotes hair regrowth. The research suggests JAK inhibitors as a promising treatment for scarring alopecia and adverse effects from EGFR-inhibitor cancer therapies. The study involved various analyses, including RNA sequencing and immunofluorescence, and used biopsy samples from 20 patients, highlighting the therapeutic potential of targeting the JAK-STAT1 pathway.
    Discuss this study in the Community →

    Research cited in this study

    22 / 22 results